Most importantly, treatment with the pharmacological CMA activator CA77.1 increases LAMP2 expression, activates CMA, restores proteostasis in AMD iPSC-RPE, promotes cellular energetic homeostasis, and shall be further explored as a therapeutic target for the treatment of AMD. Here, LAMP2 is linked to age-related macular degeneration.